<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2014-10-01 21:56:22Lysosomal storage diseases Orphan drugs Glycogen storage disease type II Hepatology Alglucosidase alfa Pharmaceutical Benefits Scheme Amyotrophic lateral sclerosis Clinical trial Health Medicine Rare diseases |
| How one patient with a rare disease coped with his genetic disorderDocID: 1r9mW - View Document |
| LUMIZYME (alglucosidase alfa) for InjectionDocID: 1qeuI - View Document |
| United States Court of Appeals for the Federal Circuit ______________________ GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP,DocID: 1oYEH - View Document |
| Pompe disease (Glycogen storage disease type II) Glycogen storage disease type II is also known as acid maltase deficiency or generalized glDocID: 1lJGD - View Document |
| May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to ImDocID: 1aiEg - View Document |